Can CDK4/6 inhibitors cause fatal lung injury?

Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: MONALEESA-3

(2018) Dennis J. Slamon et al.   JOURNAL OF CLINICAL ONCOLOGY

Pneumonitis in Patients Treated With Anti–Programmed Death-1/Programmed Death Ligand 1 Therapy

(2017) Jarushka Naidoo et al.   JOURNAL OF CLINICAL ONCOLOGY

MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2− Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy

(2017) George W. Sledge et al.   JOURNAL OF CLINICAL ONCOLOGY

Characteristics and Prognostic Impact of Pneumonitis during Systemic Anti-Cancer Therapy in Patients with Advanced Non-Small-Cell Lung Cancer

(2016) Daichi Fujimoto et al.   PLoS One

Risk of pneumonitis in cancer patients treated with immune checkpoint inhibitors: a meta-analysis

(2016) Omar Abdel-Rahman et al.   Therapeutic Advances in Respiratory Disease

Characteristics of and Risk Factors for Interstitial Lung Disease Induced by Chemotherapy for Lung Cancer

(2015) Takumi Sakurada et al.   ANNALS OF PHARMACOTHERAPY

Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer

(2015) Nicholas C. Turner et al.   NEW ENGLAND JOURNAL OF MEDICINE